引言近年来，基因编辑技术如同生物医学领域的一颗璀璨明星，吸引着全球科学家的目光。CRISPR-Cas9等DNA编辑技术的出现，为治疗遗传性疾病带来了前所未有的希望。然而，如同硬币的两面，DNA编辑技术在展现巨大潜力的同时，也面临着一些技术瓶颈，其中最 ...

Eli Lilly reports 94% Lp(a) reduction with lepodisiran in Phase 2 trials, targeting inherited heart disease risk.

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...

Eli Lilly (LLY) and Company announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA, siRNA, therapy ...

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) ...

Discover how RNA therapeutics are reshaping medicine, offering new treatments for previously undruggable targets.

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

The US Food and Drug Administration has approved fitusiran for bleeding prophylaxis in hemophilia A and B with or without ...

Novotech, a top global clinical trial provider, partners with biotech and pharma to speed siRNA therapeutic development.

Paris: Sanofi has announced that the Company has received approval from the US Food and Drug Administration (FDA) for Qfitlia ...